Colombia Biosurgery Market Overview, 2031

Key Insights

• The Colombia biosurgery market represents one of the fastest-growing national markets for surgical biomaterials in Latin America. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.
• The Colombia biosurgery market is distinguished by its universal healthcare coverage 99% of the population has access to a basic set of medical services and significant surgical volumes across orthopedic, general, and cardiovascular specialties. Healthcare expenditure in Colombia reached approximately 8.1% of GDP in 2025 (equating to USD 1,877 per capita in purchasing power parity), below the OECD average of 9.3%. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models, including the rapid adoption of minimally invasive surgical techniques and the expansion of medical device imports.
• Bone-Graft Substitutes represent the largest product category within the Colombian biosurgery market, driven by the high volume of orthopedic and trauma procedures. Colombia's aging population with 10.7% of the population aged 65 years or older in 2025 (approximately 5.7 million people) continues to drive demand for musculoskeletal interventions.Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive surgical techniques and the growing volume of laparoscopic and endoscopic procedures across Colombian hospitals.
• The regulatory environment, centered on INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), plays a decisive role in shaping market dynamics. INVIMA regulates medical devices under Decree 4725 of 2005 and subsequent regulations.

Market Outlook



• According to the research report, " Colombia Biosurgery Market Overview, 2031 Overview, 2031," published by Bonafide Research, the Colombia Biosurgery market is anticipated to grow at more than 7.35% CAGR from 2026 to 2031.
• The Colombian biosurgery market is expected to maintain robust growth through 2031, supported by favorable demographic trends, ongoing technological innovation, expanding surgical volumes, and regulatory modernization. Colombia's healthcare expenditure continues to rise, reaching 8.1% of GDP in 2025. Health spending has grown from 6.3% to 6.9% of GDP in recent years, a growth of nearly 10%. Household spending on health goods and services reached 70.2 trillion pesos (6.9% of GDP) in 2025. The ADRES budget for health financing increased from $100.4 trillion pesos in 2025 to $114.8 trillion pesos in 2026, representing a 14.3% increase. This substantial healthcare investment provides the financial foundation for sustained surgical activity and biosurgical product utilization.
• The aging Colombian population represents the most significant long-term demand driver. As of 2025, 10.7% of the population (approximately 5.7 million people) was aged 65 years or older. By 2030, the population aged 60 and over is projected to reach 9.74 million (17.5% of the total population). By 2036, the population of 60 years and older will exceed the population under 15 years of age. People aged 60 and over already number 7.6 million (14.5% of the national population). This demographic shift will drive increased demand for orthopedic, cardiovascular, and other surgical interventions. Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. Colombia is witnessing a rapid shift toward minimally invasive surgical techniques. The medical device sector is projected to grow at an expected cumulative rate of 6% (2025-2029).
• Rising surgical procedures and expanding healthcare access are key drivers propelling market expansion. Colombia performed 490,944 aesthetic procedures in 2024, including 321,408 surgical procedures and 169,536 non-surgical treatments, representing a 10% increase from the previous year. The country also recorded 148 Colombian companies engaged in hospital equipment exports, with external sales of USD 81 million in 2025.

Market Dynamics

Driver: Expanding Surgical Volumes and Aging Population
Colombia performs hundreds of thousands of surgical procedures annually across its extensive network of public and private hospitals. The country performed 490,944 aesthetic procedures in 2024 alone, with liposuction being the most common procedure at 41,280 procedures. The aging population with 10.7% aged 65 and older (approximately 5.7 million people) and projections showing this figure rising to 17.5% by 2030 continues to drive demand for musculoskeletal, cardiovascular, and ophthalmic interventions. Health spending of 8.1% of GDP provides substantial financial resources to support expanding surgical volumes. The continued expansion of surgical capacity, driven by hospital modernization and the growing network of healthcare facilities, further reinforces this demand driver. The health system budget increased from $100.4 trillion pesos in 2025 to $114.8 trillion pesos in 2026, a 14.3% increase, reflecting government commitment to healthcare expansion.



Challenge: Healthcare Infrastructure Constraints and Workforce Shortages
Despite the market's growth potential, Colombia faces significant challenges that affect the biosurgery market. The country has 2.5 physicians per 1,000 inhabitants, compared to the OECD average of 3.9, and only 1.6 nurses per 1,000 inhabitants, compared to the OECD average of 9.2. Hospital infrastructure is also constrained, with 1.9 beds per 1,000 inhabitants less than half the OECD average of 4.2. The country has only 6 CT, MRI, and PET scanners per million inhabitants, compared to the OECD average of 51. Additionally, only 46% of Colombians reported satisfaction with the availability of quality medical care, compared to the OECD average of 64%. These infrastructure and workforce constraints create pricing pressure on biosurgical products and may limit adoption of premium-priced advanced biologics. The health system faces ongoing financial pressures from the implementation of healthcare reform, with the 2026 reform projected to represent 6.3% of GDP and cost $112.6 trillion pesos.

Trend: Accelerating Regulatory Modernization and Medical Device Imports
The Colombian biosurgery market is experiencing significant transformation driven by regulatory modernization and increasing medical device imports. INVIMA regulates medical devices under Decree 4725 of 2005. The country has an active medical device ecosystem, with the Cámara de Dispositivos Médicos e Insumos para la Salud of the ANDI representing 76 companies: manufacturers (7%), multinationals (70%), and distributors (24%). The medical device sector is projected to grow at an expected cumulative rate of 6% from 2025 to 2029. The healthcare reform implemented in 2026 is projected to increase health spending to $112.6 trillion pesos (6.3% of GDP), with the budget for ADRES increasing from $100.4 trillion pesos in 2025 to $114.8 trillion pesos in 2026. Colombia's position as a growing medical device market projected to grow from USD 1.58 billion in 2025 to USD 2.34 billion by 2032 creates significant opportunities for biosurgery manufacturers.

Policies

• INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) serves as the primary regulatory authority for medical devices in Colombia. INVIMA regulates medical devices under Decree 4725 of 2005 and subsequent regulations.
• Decree 4725 of 2005 establishes the regulatory framework for sanitary registration, commercial permits, and health surveillance of medical devices for human use in Colombia.
• Sanitary registration is a mandatory requirement for manufacturing, importing, marketing, or distributing medical devices in Colombia.
• The Cámara de Dispositivos Médicos e Insumos para la Salud of the ANDI represents 76 companies in the medical device sector, including manufacturers (7%), multinationals (70%), and distributors (24%).
• Healthcare reform implementation in 2026 is projected to increase health spending to $112.6 trillion pesos (6.3% of GDP), with the ADRES budget increasing from $100.4 trillion pesos in 2025 to $114.8 trillion pesos in 2026.
• The Unique Payment Capitation (UPC) increased from 62.4 trillion pesos in 2022 to 89.5 trillion pesos in 2025, and is projected to reach 100.1 trillion pesos in 2026.

Segment Analysis

Colombia Biosurgery Market By Product
• Bone-Graft Substitutes represent the largest product category within the Colombian biosurgery market, driven by the high volume of orthopedic and trauma procedures. Colombia's aging population with 10.7% aged 65 and older and projections reaching 17.5% by 2030 continues to drive demand for musculoskeletal interventions. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors, widely utilized in trauma fixation, spinal fusion, and joint replacement procedures.
• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. With Colombia performing 321,408 surgical procedures in 2024 alone, demand for hemostatic products is substantial and growing.
• Surgical Sealants and Adhesives represent the fastest-growing product category in the Colombian biosurgery market, driven by increasing adoption of minimally invasive surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The growing volume of laparoscopic and endoscopic procedures across Colombian hospitals supports the expansion of this segment.
• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial.
• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in Colombian hospitals.
• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage. The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.

Colombia Biosurgery Market By Application • Orthopedic Surgery is the largest application area for biosurgical products in Colombia, driven by the high volume of trauma surgeries, joint replacements, and spinal procedures. Colombia's aging population with 10.7% aged 65 and older continues to drive demand for musculoskeletal interventions. The Colombian Society of Orthopedics and Traumatology represents the specialty.
• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair. Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers. The Colombian Association of Surgery (Revista Colombiana de Cirugía) serves as the official dissemination body.
• Cardiovascular Surgery represents the fastest-growing application area in the Colombian biosurgery market, driven by the high prevalence of cardiovascular disease and the aging population. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures. Cardiovascular diseases, along with cancer and diabetes, are among the leading causes of household health spending in Colombia.
• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. The aging population and increasing incidence of neurological conditions drive demand in this specialty.
• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery. Aesthetic procedures in Colombia reached 490,944 interventions in 2024.
• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement.
• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.
• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions.

Colombia Biosurgery Market By Source/Origin • Biologic products represent the largest source category in the Colombian biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. INVIMA's rigorous requirements for biological materials ensure high safety standards.
• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the Colombian market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The Colombian healthcare system's emphasis on cost-effectiveness and the growing domestic manufacturing sector favor synthetic alternatives for certain applications.

Colombia Biosurgery Market By End-User • Hospitals remain the largest end-user segment for biosurgical products in Colombia, accounting for the majority of revenue. Colombia has achieved 99% healthcare coverage of its population with a basic set of medical services. Public hospitals under the national, departmental, and municipal systems perform the majority of surgical procedures. The health system has experienced significant expansion, with 2,897 new hospital openings versus 1,790 closures between 2022 and 2025.
• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the Colombian biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity supports the adoption of biosurgical products in these settings.
• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.

Colombia Biosurgery Market Economics

• Colombia’s biosurgery market operates through contributory and subsidized healthcare regimes, with 99% population coverage. Healthcare expenditure reached approximately 8.1% of GDP in 2025, while household spending on health goods and services reached COP 70.2 trillion. The UPC increased to COP 89.5 trillion in 2025, and the ADRES budget is expected to reach COP 114.8 trillion in 2026. Manufacturers must navigate public tenders, private procurement, and pricing pressures.
• Colombia’s healthcare infrastructure is expanding, with 2,897 new hospitals opening between 2022 and 2025. However, hospital capacity remains constrained, with only 1.9 beds per 1,000 inhabitants compared with the OECD average of 4.2. Workforce shortages are also significant, with 2.5 physicians and 1.6 nurses per 1,000 inhabitants. These infrastructure and workforce gaps may influence surgical capacity and demand for efficient biosurgical technologies.
• The medical device sector is expanding, supported by domestic manufacturing, multinational companies, and growing exports. Colombia’s medical device market is projected to increase from USD 1.58 billion in 2025 to USD 2.34 billion by 2032. Minimally invasive procedures and advanced biomaterials are gaining adoption, while 148 Colombian companies generated USD 81 million in hospital equipment exports in 2025. INVIMA remains central to product approval and regulatory compliance.
• Colombia’s long-term biosurgery outlook is positive, supported by population growth, ageing demographics, healthcare investment, and technology adoption. The population reached approximately 53.06 million in 2025, with 10.7% aged 65 or older, projected to reach 17.5% by 2030. The biosurgery market is expected to grow at more than 7.35% CAGR from 2026–2031. Manufacturers that manage regulatory, procurement, and workforce challenges can benefit from Colombia’s rapidly expanding market.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Biosurgery Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Bone-Graft Substitutes
• Hemostatic Agents
• Surgical Sealants & Adhesives
• Adhesion Barriers
• Soft-Tissue Attachments
• Staple-Line Reinforcement

By Application:
• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Urological Surgery
• Other surgeries (Thoracic surgeries & more)

By Source/Origin
• Biologic
• Synthetic / Semi-synthetic

By End-user:
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others